Avacta’s AVA6000 Shows Promise in Phase 1 Trial

Avacta Group plc (GB:AVCT) has released an update.

Avacta Group plc’s innovative cancer drug AVA6000 has shown promising safety and efficacy results in a Phase 1 trial presented at the ESMO Congress. The drug, utilizing a unique delivery platform, demonstrated positive responses in solid tumors, particularly in patients with high levels of the FAP enzyme, and had a favorable safety profile with reduced cardiac toxicity compared to traditional doxorubicin treatments.

For further insights into GB:AVCT stock, check out TipRanks’ Stock Analysis page.